
EarlySense
Total Raised
$127MInvestors Count
19Deal Terms
2Funding, Valuation & Revenue
11 Fundings
EarlySense has raised $127M over 11 rounds.
EarlySense's latest funding round was a Acquired for on February 1, 2021.
EarlySense's latest post-money valuation is from February 2021.
Sign up for a free demo to see EarlySense's valuations in February 2021 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
2/1/2021 | Acquired | 1 | ||||
1/7/2019 | Series H | $39M | 2 | |||
6/1/2016 | Series G | $25M | 18 | |||
4/14/2015 | Series F - II | |||||
1/20/2015 | Series F |
Date | 2/1/2021 | 1/7/2019 | 6/1/2016 | 4/14/2015 | 1/20/2015 |
|---|---|---|---|---|---|
Round | Acquired | Series H | Series G | Series F - II | Series F |
Amount | $39M | $25M | |||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 1 | 2 | 18 |
EarlySense Deal Terms
2 Deal Terms
EarlySense's deal structure is available for 2 funding rounds, including their Acquired from February 01, 2021.
Round | Acquired | Series A |
|---|---|---|
Funding Date | ||
Pre-Money Valuation | ||
Post-Money Valuation | ||
Amount Raised | ||
Shares Authorized | ||
Issuance Price | ||
Dividend Rate | ||
Liquidation Preferences | ||
Liquidation Price | ||
Participation | ||
Conversion Price | ||
Anti Dilution | ||
General Voting | ||
Board Voting | ||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acquired | |||||||||||||||
Series A |
EarlySense Investors
19 Investors
EarlySense has 19 investors. Hillrom invested in EarlySense's Acquired funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
1/7/2019 | 2/1/2021 | 2 Series H, Acquired (2021) | Corporation | Illinois | ||
6/10/2010 | 1/7/2019 | 6 Series C, Series D (2010), Series E (2012), Series F (2015), Series G (2016), Series H (2019) | Venture Capital | Israel | ||
11/12/2012 | 1/7/2019 | 4 Series E, Series F (2015), Series G (2016), Series H (2019) | Venture Capital | Illinois | ||
Venture Capital | Singapore | |||||
Corporate Venture | California |
First funding | 1/7/2019 | 6/10/2010 | 11/12/2012 | ||
|---|---|---|---|---|---|
Last Funding | 2/1/2021 | 1/7/2019 | 1/7/2019 | ||
Investor | |||||
Rounds | 2 Series H, Acquired (2021) | 6 Series C, Series D (2010), Series E (2012), Series F (2015), Series G (2016), Series H (2019) | 4 Series E, Series F (2015), Series G (2016), Series H (2019) | ||
Board Seats | |||||
Type | Corporation | Venture Capital | Venture Capital | Venture Capital | Corporate Venture |
Location | Illinois | Israel | Illinois | Singapore | California |
Compare EarlySense to Competitors

binx health focuses on point-of-care molecular diagnostics within the healthcare sector. The company offers diagnostic solutions that provide testing solutions for sexually transmitted infections such as chlamydia and gonorrhea. binx health was formerly known as Atlas Genetics. It was founded in 2005 and is based in Cambridge, Massachusetts.
NIR Diagnostics is developing a diagnostic device to quantitatively assess the progress of the wound healing process. Per the company, the device has the potential to be a more accurate, more rapid, and less expensive method of wound assessment compared to those currently on the market.
After two years of development, testing and continuous improvement and trials at various hospitals, INFLO Infusion Flow Rate Monitor was introduced. INFLO is a microprocessor-controlled device with high level of accuracy, which can be used to monitor the infusion flow rate. Its low cost and low operating expenses as well as long life cycle aims to make it an alternative to the expensive infusion monitoring devices and aims to give accuracy and safety with inexpensive infusion sets.
SonoMedix is developing a device to monitor blood coagulation and hemostatic status, using NanoAcoustic Blood Analyzer (NABA) technology licensed from Drexel University. SonoMedix is developing a working NABA-based prototype of a device to be used at home to measure the prothombin time, a measure of blood coagulation, in patients taking the anticoagulant drug, warfarin (Coumadin ). The device will allow the patients who need to perform this testing to use a smaller amount of blood than currently marketed devices, which will allow them to obtain blood from sites other than fingers, reducing the pain of obtaining the sample. The small sample size is currently being validated.
findtheDOT designs and develops technology to match medications to patients and physician orders. The Company's printed code mark and portable, wireless code reader provide a practical means of validating medications at the patient bedside.

VivoMetrics provides continuous ambulatory monitoring products and services for the collection, analysis, and reporting of patient specific physiologic data serving pharmaceutical, biotechnology, and device companies.
Loading...

